drugset / Trial / NCT00240929
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
RandomizedCrossoverDouble-blindTreatment
Summary
A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.
Timeline
- Start
- 2002-09
- Primary completion
- —
- Completion
- 2003-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palivizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.